## STZ: Constellation Brands, Inc. - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -1.8% below STRENGTH zone (4.0-10.0%); PEG 1.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($131.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Diageo plc $DEO Shares Sold by Roffman Miller Associates Inc. PA**
- Source: MarketBeat | 20251223T121017 | Somewhat-Bullish | Relevance: 69%
- Roffman Miller Associates Inc. PA reduced its stake in Diageo plc by 15.1% in Q3, selling 13,799 shares. Despite this, other institutions significantly increased their holdings, with Arrowstreet Capital notably adding 559,547 shares. Analyst ratings are mixed, with a consensus "Hold" and an average price target of $119, while the stock currently trades around $86.79.

**2. Canopy Growth (CGC) Stock Outlook December 2025: Debt Prepayment, Lawsuit Pressure and a Highâ€‘Risk Turnaround**
- Source: ts2.tech | 20251221T110913 | Neutral | Relevance: 64%
- Canopy Growth's (CGC) stock outlook for December 2025 highlights a company undergoing a high-risk turnaround, marked by recent debt prepayments and improved Q2 FY2026 earnings with narrowed losses and increased margins. Despite these positive financial adjustments, the company faces pressures from a new U.S. securities class action lawsuit and a divided analyst community regarding its future potential. Its balance sheet is stronger due to equity raises, but profitability remains elusive, making it a speculative investment.

**3. Osaic Holdings Inc. Purchases 29,674 Shares of Diageo plc $DEO**
- Source: MarketBeat | 20251222T000923 | Somewhat-Bullish | Relevance: 63%
- Osaic Holdings Inc. significantly increased its stake in Diageo plc (NYSE:DEO) during Q2, purchasing an additional 29,674 shares to bring its total holdings to 99,998 shares, valued at approximately $10.10 million. Other institutional investors like Arrowstreet Capital, Martin Capital Partners, and Philip James Wealth Management also increased their positions in the company. Despite these purchases, analysts currently have a "Hold" consensus rating for Diageo, with a price target of $119.00.

**4. Granite Construction stock reaches all-time high of 117.19 USD**
- Source: Investing.com | 20251222T160940 | Somewhat-Bullish | Relevance: 63%
- Granite Construction Inc.'s stock hit an all-time high of $117.19, reflecting a 29.06% increase over the past year and a 30% gain in six months. The company's recent strong performance is attributed to a robust market and strategic initiatives, despite an InvestingPro overbought RSI indication. Analysts project a $6.23 EPS and 10% revenue growth for the fiscal year, with recent Q3 earnings surpassing EPS expectations and the company winning a $24 million contract.

**5. Mbx Biosciences stock hits all-time high of 34.85 USD**
- Source: Investing.com | 20251223T120840 | Somewhat-Bullish | Relevance: 62%
- MBX Biosciences (MBX) stock reached an all-time high of $34.85, reflecting a 49.41% increase over the past year and a 212.32% surge over six months. Despite trading slightly above its Fair Value, the company demonstrates financial stability with a strong balance sheet and a $1.37 billion market capitalization. Analysts offer varied outlooks, with price targets ranging from $18 to $80, following positive Phase 2 trial results for its lead drug candidate, canvuparatide.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Jefferies | $154 | $170 | -9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Jefferies | down | Hold |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (+3.2%)
- Berkshire Hathaway, : 7.7% (0.0%)
- Blackrock Inc.: 6.1% (-2.0%)
- Capital World Invest: 3.8% (-43.3%)
- State Street Corpora: 3.8% (-4.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.4% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 13.3% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bearish (6 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $24.2B |
| Beta | 0.46 |
| 52W Range | $126.45 - $228.89 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 11.2 |
| Current P/E | 12.1 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.6% to -1.8% (-4.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.8pp (needs >4.0% for momentum thesis). Below SMA200 (0.87x), long-term trend not supportive. MACD histogram bearish (-0.64), momentum weakening. RSI neutral at 50. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.79% (CS: 34) | Neutral |
| RSI_14 | 50.4 | Neutral |
| MACD Histogram | -0.64 | Bearish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 1.021x | Above |
| vs SMA200 | 0.867x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $139.22
- **Stop Loss:** $131.64 (5.4% risk)
- **Target:** $146.80 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 79
- **Position Value:** $10,998.38
- **Portfolio %:** 11.00%
- **Risk Dollars:** $600.00
- **Risk Per Trade:** 0.60%
- **Modifiers:** L1 120% | L2 50% | Combined 0.60x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-07 (Est: $2.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.41 | $3.63 | +6.5% |
| 2025Q2 | $3.29 | $3.22 | -2.3% |
| 2025Q1 | $2.27 | $2.63 | +15.9% |
| 2024Q4 | $3.31 | $3.25 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*